These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 32282867

  • 1. Tenapanor for constipation-predominant irritable bowel syndrome.
    Siddiqui S, Cash BD.
    Drugs Today (Barc); 2020 Mar; 56(3):203-210. PubMed ID: 32282867
    [Abstract] [Full Text] [Related]

  • 2. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
    Chey WD, Lembo AJ, Rosenbaum DP.
    Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
    [Abstract] [Full Text] [Related]

  • 3. Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome.
    Zielińska M, Wasilewski A, Fichna J.
    Expert Opin Investig Drugs; 2015 May; 24(8):1093-9. PubMed ID: 26065434
    [Abstract] [Full Text] [Related]

  • 4. Tenapanor for the treatment of irritable bowel syndrome with constipation.
    Sinagra E, Rossi F, Raimondo D, Conoscenti G, Anderloni A, Guarnotta V, Maida M.
    Expert Rev Clin Pharmacol; 2020 May; 13(5):473-479. PubMed ID: 32478632
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).
    Chey WD, Lembo AJ, Rosenbaum DP.
    Am J Gastroenterol; 2020 Feb; 115(2):281-293. PubMed ID: 31934897
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).
    Chey WD, Lembo AJ, Yang Y, Rosenbaum DP.
    Am J Gastroenterol; 2021 Jun 01; 116(6):1294-1303. PubMed ID: 33337659
    [Abstract] [Full Text] [Related]

  • 7. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH, Luthin DR.
    Pharmacotherapy; 2015 Jun 01; 35(6):613-30. PubMed ID: 26016701
    [Abstract] [Full Text] [Related]

  • 8. A pharmacokinetic evaluation of tenapanor for the treatment of irritable bowel syndrome with constipation: an update of the literature.
    Currò D, Ianiro G, Gasbarrini A.
    Expert Opin Drug Metab Toxicol; 2023 Dec 01; 19(12):889-894. PubMed ID: 38108081
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.
    Black CJ, Burr NE, Quigley EMM, Moayyedi P, Houghton LA, Ford AC.
    Gastroenterology; 2018 Dec 01; 155(6):1753-1763. PubMed ID: 30144426
    [Abstract] [Full Text] [Related]

  • 10. Tenapanor: First Approval.
    Markham A.
    Drugs; 2019 Nov 01; 79(17):1897-1903. PubMed ID: 31677150
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study.
    Lembo AJ, Friedenberg KA, Fogel RP, Edelstein S, Zhao S, Yang Y, Rosenbaum DP, Chey WD.
    Neurogastroenterol Motil; 2023 Nov 01; 35(11):e14658. PubMed ID: 37668173
    [Abstract] [Full Text] [Related]

  • 13. NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons.
    King AJ, Chang L, Li Q, Liu L, Zhu Y, Pasricha PJ, Wang J, Siegel M, Caldwell JS, Edelstein S, Rosenbaum DP, Kozuka K.
    Am J Physiol Gastrointest Liver Physiol; 2024 May 01; 326(5):G543-G554. PubMed ID: 38252683
    [Abstract] [Full Text] [Related]

  • 14. Update on Pharmacotherapy for Irritable Bowel Syndrome.
    Munjal A, Dedania B, Cash B.
    Curr Gastroenterol Rep; 2019 Apr 25; 21(6):25. PubMed ID: 31025114
    [Abstract] [Full Text] [Related]

  • 15. Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
    Miner PB.
    Expert Rev Gastroenterol Hepatol; 2020 Feb 25; 14(2):71-84. PubMed ID: 31985305
    [Abstract] [Full Text] [Related]

  • 16. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD.
    Adv Ther; 2009 May 25; 26(5):519-30. PubMed ID: 19444393
    [Abstract] [Full Text] [Related]

  • 17. Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome.
    Munjal A, Dedania B, Cash BD.
    Expert Opin Pharmacother; 2020 Jan 25; 21(1):63-71. PubMed ID: 31738621
    [Abstract] [Full Text] [Related]

  • 18. Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options.
    Wechsler EV, Shah ED.
    Drugs; 2021 Nov 25; 81(17):1953-1968. PubMed ID: 34727333
    [Abstract] [Full Text] [Related]

  • 19. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM, Shiff SJ, Quigley EM.
    Curr Med Res Opin; 2013 Feb 25; 29(2):149-60. PubMed ID: 23198977
    [Abstract] [Full Text] [Related]

  • 20. Tenapanor (Ibsrela) for the Treatment of Irritable Bowel Syndrome With Constipation.
    Curtis S, Curtis M.
    Am Fam Physician; 2022 Jun 01; 105(6):656-658. PubMed ID: 35704831
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.